According to Moody's Investors Service, the global pharmaceutical industry is on track to realize annual earnings growth of 3 percent to 4 percent over the next 12 to 18 months. Moody's believes the strong underlying fundamentals of the industry will be able to offset the effect of the strong U.S. dollar and political environment bringing increased scrutiny on the price of drugs.